Feedback / Questions
prexasertib (ACR-368) - Acrivon Therap
ACR-368: Protection of composition-of-matter patent until Oct 2030
(Acrivon Therapeutics)
-
Dec 27, 2024 -
Corporate Presentation: Protection of patent related to salt form until Apr 2037
Patent
•
Oncology
https://ir.acrivon.com/static-files/02c9f0f3-f8c6-45b2-b9a1-a5a2a6ea7848
Dec 27, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious